EntryPoint Capital’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
HA
TCM
EntryPoint Capital's CTKB Position: Q2 2026 in Review
EntryPoint Capital opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 22,871 shares worth $101K. The stake represents 0.02% of the portfolio and ranks #741 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in CTKB as recently as Q2 2025.
EntryPoint Capital first reported a position in CTKB in Q4 2023 and has held it in 5 quarters since. The position peaked at $553K in Q2 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.
- EntryPoint Capital held 22,871 shares of Cytek Biosciences worth $101K as of Q2 2026.
- Cytek Biosciences was a new EntryPoint Capital position in Q2 2026.
- Cytek Biosciences made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #741 holding.
- EntryPoint Capital first reported a position in Cytek Biosciences in Q4 2023 and has held it in 5 quarters since.
- EntryPoint Capital's Cytek Biosciences position peaked at $553K in Q2 2024.
- 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.